Drug
Donidalorsen
Donidalorsen: highest development phase Approved, developed by Ionis Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| DAWNZERA (AUTOINJECTOR) | Approved | |
| Donidalorsen NCT05139810 | Phase 3 | Hereditary Angioedema |
| Donidalorsen NCT07298447 | Phase 3 | Hereditary Angioedema (HAE) |
| Donidalorsen NCT04307381 | Phase 2 | Hereditary Angioedema |
| Donidalorsen NCT03263507 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Donidalorsen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.